T1	PROC 46 60	Ensayo clínico
#1	AnnotatorNotes T1	C0008976; Clinical Trials; Research Activity
T2	PROC 66 87	evaluar biomarcadores
T3	ANAT 106 114	vascular
#2	AnnotatorNotes T3	C0005847; Blood Vessel; Body Part, Organ, or Organ Component | C0042591; Vessel Positions; Body Location or Region
T4	PROC 137 151	ENSAYO CLÍNICO
#3	AnnotatorNotes T4	C0008976; Clinical Trials; Research Activity
T5	PROC 157 167	EVALUACIÓN
#4	AnnotatorNotes T5	C1261322; Evaluation procedure; Health Care Activity
T6	CHEM 175 186	ADIPOQUINAS
#5	AnnotatorNotes T6	C1955907; Adipokines; Amino Acid, Peptide, or Protein · Biologically Active Substance
T7	PROC 222 230	PREVENIR
#6	AnnotatorNotes T7	C0199176; Prophylactic treatment; Therapeutic or Preventive Procedure
T8	ANAT 249 257	VASCULAR
#7	AnnotatorNotes T8	C0005847; Blood Vessel; Body Part, Organ, or Organ Component | C0042591; Vessel Positions; Body Location or Region
T9	PROC 543 579	test de tolerancia oral a la glucosa
#8	AnnotatorNotes T9	C0029161; Oral Glucose Tolerance Test; Diagnostic Procedure
T10	PROC 679 682	IMC
#9	AnnotatorNotes T10	C0005893; Body mass index procedure; Diagnostic Procedure | C3698309; Measurement of body mass index; Health Care Activity
T11	CHEM 572 579	glucosa
#10	AnnotatorNotes T11	C0017725; glucose; Biologically Active Substance · Organic Chemical · Pharmacologic Substance
T12	PROC 597 620	Hemoglobina glicosilada
#11	AnnotatorNotes T12	C0202054; Glucohemoglobin measurement; Laboratory Procedure
T13	DISO 885 915	insuficiencia hepática o renal
#12	AnnotatorNotes T13	C0085605; Liver Failure; Disease or Syndrome + C0035078; Kidney Failure; Disease or Syndrome
T14	DISO 649 657	Obesidad
#13	AnnotatorNotes T14	C0028754; Obesity; Disease or Syndrome
T15	PROC 840 867	tratamiento hipoglucemiante
T16	ANAT 910 915	renal
#14	AnnotatorNotes T16	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T17	DISO 923 945	insuficiencia cardíaca
#15	AnnotatorNotes T17	C0018801; Heart failure; Disease or Syndrome
T18	DISO 971 991	procesos neoplásicos
#16	AnnotatorNotes T18	C0027671; Neoplastic Processes; Neoplastic Process
T19	DISO 1005 1022	basalioma cutáneo
T20	PROC 1107 1117	evaluación
#17	AnnotatorNotes T20	C1261322; Evaluation procedure; Health Care Activity
T21	DISO 281 292	PREDIABETES
#18	AnnotatorNotes T21	C0362046; Prediabetes syndrome; Disease or Syndrome
T22	DISO 405 416	prediabetes
#19	AnnotatorNotes T22	C0362046; Prediabetes syndrome; Disease or Syndrome
T23	PROC 422 430	Glucemia
#20	AnnotatorNotes T23	C0392201; Blood glucose measurement; Laboratory Procedure
T24	PROC 492 500	Glucemia
#21	AnnotatorNotes T24	C0392201; Blood glucose measurement; Laboratory Procedure
T25	PROC 622 627	HbA1c
#22	AnnotatorNotes T25	C0202054; Glucohemoglobin measurement; Laboratory Procedure
T26	CHEM 852 867	hipoglucemiante
#23	AnnotatorNotes T26	C0020616; Hypoglycemic Agents; Pharmacologic Substance
T27	ANAT 899 907	hepática
#24	AnnotatorNotes T27	C0023884; Liver; Body Part, Organ, or Organ Component | C1278929; Entire liver; Body Part, Organ, or Organ Component
T28	ANAT 937 945	cardíaca
#25	AnnotatorNotes T28	C0018787; Heart; Body Part, Organ, or Organ Component | C1281570; Entire heart; Body Part, Organ, or Organ Component
T29	PROC 748 772	consentimiento informado
#26	AnnotatorNotes T29	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T30	ANAT 1015 1022	cutáneo
#27	AnnotatorNotes T30	C0011646; Dermis; Tissue | C1123023; Skin; Body System
T31	Date 13 17	2018
T32	PHYS 234 248	ENVEJECIMIENTO
#28	AnnotatorNotes T32	C0001811; Aging; Organism Function
T33	Age 327 345	entre 18 y 60 años
T37	Duration 525 538	las dos horas
T39	Dose 583 592	75 gramos
T40	LIVB 803 812	Pacientes
#29	AnnotatorNotes T40	C0030705; Patients; Patient or Disabled Group
T41	LIVB 871 880	Pacientes
#30	AnnotatorNotes T41	C0030705; Patients; Patient or Disabled Group
T43	Neg_cue 993 1004	exceptuando
T44	LIVB 1026 1035	Pacientes
#31	AnnotatorNotes T44	C0030705; Patients; Patient or Disabled Group
T46	LIVB 1129 1141	investigador
#32	AnnotatorNotes T46	C0035173; Research Personnel; Professional or Occupational Group
T47	LIVB 1145 1164	Mujeres embarazadas
#33	AnnotatorNotes T47	C0033011; Pregnant Women; Population Group
T42	PHYS 1153 1164	embarazadas
#34	AnnotatorNotes T42	C0032961; Pregnancy; Organism Function
T45	PHYS 91 105	envejecimiento
#35	AnnotatorNotes T45	C0001811; Aging; Organism Function
T34	PROC 964 968	NYHA
#36	AnnotatorNotes T34	C4706236; Assessment using New York Heart Association Classification; Health Care Activity
A1	Assertion T19 Negated
#37	AnnotatorNotes T2	C1879847; Biomarker Analysis; Laboratory Procedure
#38	AnnotatorNotes T19	C4721806; Skin Basal Cell Carcinoma; Neoplastic Process (?)
T35	Observation 1077 1100	incluidos en el estudio
A2	Assertion T35 Negated
#39	AnnotatorNotes T35	C1302261; Patient eligible for clinical trial; Finding (?)
T36	Neg_cue 1061 1063	no
T38	Result_or_Value 683 693	≥ 35 kg/m2
R1	Has_Result_or_Value Arg1:T10 Arg2:T38	
T48	Quantifier_or_Qualifier 658 677	grado II o superior
R2	Has_Quantifier_or_Qualifier Arg1:T14 Arg2:T48	
T49	Result_or_Value 629 645	entre 5,7 y 6,4%
R3	Has_Result_or_Value Arg1:T25 Arg2:T49	
R4	Has_Result_or_Value Arg1:T12 Arg2:T49	
T50	Result_or_Value 501 522	entre 140 y 199 mg/dl
R5	Has_Result_or_Value Arg1:T24 Arg2:T50	
R6	Overlap Arg1:T24 Arg2:T37	
R7	Before Arg1:T9 Arg2:T24	
R8	Has_Dose_or_Strength Arg1:T11 Arg2:T39	
R9	Used_for Arg1:T11 Arg2:T9	
T51	Result_or_Value 437 458	entre 100 y 125 mg/dl
T52	Quantifier_or_Qualifier 459 484	repetida en dos ocasiones
R10	Has_Result_or_Value Arg1:T23 Arg2:T51	
R11	Has_Quantifier_or_Qualifier Arg1:T23 Arg2:T52	
T53	Quantifier_or_Qualifier 431 436	basal
#40	AnnotatorNotes T53	C1442488; Baseline; Quantitative Concept
R12	Has_Quantifier_or_Qualifier Arg1:T23 Arg2:T53	
R14	Location_of Arg1:T3 Arg2:T45	
R15	Location_of Arg1:T8 Arg2:T32	
R16	Before Arg1:T7 Arg2:T32	
R17	Used_for Arg1:T6 Arg2:T7	
R18	Experiences Arg1:T40 Arg2:T15	
R19	Used_for Arg1:T26 Arg2:T15	
R20	Location_of Arg1:T16 Arg2:T13	
R21	Location_of Arg1:T27 Arg2:T13	
R22	Experiences Arg1:T41 Arg2:T13	
R23	Experiences Arg1:T41 Arg2:T17	
R24	Experiences Arg1:T41 Arg2:T18	
R25	Experiences Arg1:T41 Arg2:T19	
R26	Negation Arg1:T43 Arg2:T19	
R27	Location_of Arg1:T30 Arg2:T19	
T54	Result_or_Value 946 960	grado III o IV
R28	Has_Result_or_Value Arg1:T34 Arg2:T54	
R29	Location_of Arg1:T28 Arg2:T17	
T55	Quantifier_or_Qualifier 916 921	grave
#41	AnnotatorNotes T55	C1547227; Severe - Severity of Illness Code; Intellectual Product
R30	Has_Quantifier_or_Qualifier Arg1:T13 Arg2:T55	
R31	Experiences Arg1:T41 Arg2:T34	
R32	Negation Arg1:T36 Arg2:T35	
R33	Has_Quantifier_or_Qualifier Arg1:T44 Arg2:T35	
R34	Experiences Arg1:T44 Arg2:T20	
R35	Before Arg1:T20 Arg2:T35	
R36	Experiences Arg1:T47 Arg2:T42	
#42	AnnotatorNotes T52	C1948050; Twice (Numerical Qualifier); Quantitative Concept 
T56	Observation 704 721	acepte participar
R37	Overlap Arg1:T56 Arg2:T29	
A3	Experiencer T40 Patient
A4	Experiencer T41 Patient
A5	Experiencer T44 Patient
A6	Experiencer T46 Other
A7	Experiencer T47 Patient
